Effects of inactivation-resistant agonists on the signalling, desensitization and down-regulation of bradykinin B 2 receptors

British Journal of Pharmacology

Volumn 158, Issue 5, 2009, Pages 1375-1386

  Bawolak, Marie Thérèse ^a   Fortin, Sébastien ^a   Bouthillier, Johanne ^a   Adam, Albert ^b   Gera, Lajos ^c   Gaudreault, René C ^a   Marceau, François ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

arrestin; B 9972; B 2 receptor; Bradykinin; C fos; Compound 47a; ERK1 2; LF 16 0687; Receptor downregulation; Receptor endocytosis

Indexed keywords

ANATIBANT; BETA ARRESTIN 1; BETA ARRESTIN 2; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR AGONIST; CALCIUM; COMPOUND 47A; GREEN FLUORESCENT PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PROTEIN C FOS; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM TRANSPORT; CELL STRAIN HEK293; CONTROLLED STUDY; ENDOCYTOSIS; EPIFLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RABBIT; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN; VASCULAR SMOOTH MUSCLE;

AMINOPYRIDINES; ANIMALS; ARRESTINS; BENZIMIDAZOLES; BINDING, COMPETITIVE; CALCIUM; CELL LINE; DOWN-REGULATION; HUMANS; MUSCLE, SMOOTH, VASCULAR; OLIGOPEPTIDES; QUINOLINES; RABBITS; RADIOLIGAND ASSAY; RECEPTOR, BRADYKININ B2; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; UMBILICAL VEINS;

EID: 70849131152     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00409.x     Document Type: Article

References (46)

1. Abe Y, Kayakiri H, Satoh S, Inoue T, Sawada Y, Imai K et al. (1998a). A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the Basic Framework. J Med Chem 41: 564-578. (Pubitemid 28093091)
2. Abe Y, Kayakiri H, Satoh S, Inoue T, Sawada Y, Inamura N et al. (1998b). A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1, 2-ajpyridlne moiety. J Med Chem 41: 4062-4079.
3. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition (2008 revision). Br J Pharmacol 153 (Suppl. 2): S1-S209.
4. 2 receptor. Mol Pharmacol 52: 16-20.
5. Bachvarov DR, Houle S, Bachvarova M, Bouthillier J, Adam A, Marceau F (2001). Bradykinin B2 receptor endocytosis, recycling, and downregulation assessed using green fluorescent protein conjugates. J Pharmacol Exp Ther 297: 19-26. (Pubitemid 32242559)
6. Bawolak MT, Marceau F (2007). Does zaltoprofen antagonize the bradykinin receptors? Regul Pept 140: 125-130.
7. Bawolak MT, Gera L, Morissette G, Stewart JM, Marceau F (2007). B-9972 (D-Arg-[Hyp3,Ig15,Oic7,Ig18]-bradykinin) is an inactivationresistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3, Ig15,D-Ig17,Oic8]-bradykinin): pharmacologic profile and effective induction of receptor degradation. J Pharmacol Exp Ther 323: 534-546.
8. Bernier V, Lagacé M, Lonergan M, Arthus MF, Bichet DG, Bouvier M (2007). Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol Endocrinol 18: 2074-2084. (Pubitemid 39006510)
9. Blaukat A, Abd Alia S, Lohse MJ, Müller-Esterl W (1996). Ligandinduced phosphorylation/dephosphorylation of the endogenous bradykinin B2 receptor from human fibroblasts. J Biol Chem 271: 32366-32374. (Pubitemid 26422278)
10. Blaukat A, Herzer K, Schroeder C, Bachmann M, Nash N, Müller-Esterl W (1999). Overexpression and functional characterization of kinin receptors reveal subtype-specific phosphorylation. Biochemistry 38: 1300-1309. (Pubitemid 129501328)
11. Brechter AB, Lerner UH (2002). Characterization of bradykinin receptors in a human osteoblastic cell line. Regul Pept 103: 39-51. (Pubitemid 34001635)
12. Burelout C, Thibault N, Levasseur S, Simard S, Naccache PH, Bourgoin SG (2004). Prostaglandin E2 inhibits the phospholipase D pathway stimulated by formyl-methionyl-leucyl-phenylalanine in human neutrophils. Involvement of EP2 receptors and phosphatidylinositol 3-kinase. Mol Pharmacol 66: 293-301. (Pubitemid 38989486)
13. Cuthbert AW (1999). Anion secretory effects of a non-peptide mimic of bradykinin (FR190997) on mouse colon epithelium, immunopharmacotogy 45: 191-198.
14. DeWlre SM, Kim J, Whalen EJ, Ahn S, Chen M, Lefkowitz RJ (2008). β-arrestin-mediated signaling regulates protein synthesis. J Biol Chem 283: 10611-10620.
15. Faussner A, Proud D, Towns M, Bathon JM (1998). Influence of the cytosollc carboxyl termini of human B1 and B2 kinin receptors on receptor sequestration, ligand internalization, and signal transduction. J Biol Chem 273: 2617-2623. (Pubitemid 28133903)
16. Fortin JP, Marceau F (2006). Advances in the development of bradykinin receptor ligands. Curr Top Med Chem 6: 1353-1363. (Pubitemid 44144921)
17. Glauser DA, Schlegel W (2007). Sequential actions of ERK1/2 on the AP-1 transcription factor allow temporal integration of metabolic signals in pancreatic β cells. FASEB J 21: 3240-3249. (Pubitemid 47565542)
18. Gobeil FJr, Montagne M, Inamura N, Regoli D (1999). Characterization of non-peptide bradykinin B2 receptor agonist (FR 190997) and antagonist (FR 173657). Immunopharmacology 43: 179-185.
19. Hamdan FF, Rochdi MD, Breton B, Fessart D, Michaud DE, Charest PG et al. (2007). Unraveling G protein-coupled receptor endocytosis pathways using real-time monitoring of agonist-promoted interaction between β-arrestins and AP-2. J Biol Chem 282: 29089-29100. (Pubitemid 350043377)
20. Hayashi I, Ishihara K, Kumagai Y, Majima M (2001). Proinflammatory characteristics of a nonpeptide bradykinin mimic, FR190997, in vivo. Br J Pharmacol 133: 1296-1306. (Pubitemid 32783490)
21. Houle S, Marceau F (2003). Wortmannin alters the intracellular trafficking of the bradykinin B2 receptor: role of phosphoinositide 3-kinase and Rab5. Biochem J 375: 151-158. (Pubitemid 37255390)
22. Houle S, Larrivée JF, Bachvarova M, Bouthillier J, Bachvarov DR, Marceau F (2000). Antagonist-induced intracellular sequestration of rabbit bradykinin B2 receptor. Hypertension 35: 1319-1325. (Pubitemid 30413671)
23. Houle S, Molinaro G, Adam A, Marceau F (2003). Tissue kallikrein actions at the rabbit natural or recombinant kinin B2 receptors. Hypertension 41: 611-617. (Pubitemid 36314640)
24. Kalatskaya I, Schüssler S, Seidl C, Jochum M, Faussner A (2006). C-terminal fusion of eGFP to the bradykinin B2 receptor strongly affects down-regulation but not receptor internalization or signaling. Biol Chem 387: 603-610. (Pubitemid 44071463)
25. Kramarenko II, Bunni MA, Motlnelli TA, Raymond JR, Garnovskaya MN (2009). Identification of functional bradykinin B2 receptors endogenously expressed in HEK 293 cells. Biochem Pharmacol 77: 269-276.
26. 2- adrenoceptors; comparison with the unmodified receptor. Br J Pharmacol 130: 1825-1832.
27. Majima M, Hayashi I, Inamura N, Fujita T, Ogino M (2000). A nonpeptide mimic of bradykinin blunts the development of hypertension in young spontaneously hypertensive rats. Hypertension 35: 437-442. (Pubitemid 30054213)
28. Marceau F, Levesque L, Drapeau G, Rioux F, Salvino JM, Wolfe H et al (1994). Effects of peptide and nonpeptide antagonists of the bradykinin B2 receptors on the venoconstrictor action of bradykinin. J Pharmacol Exp Ther 269: 1136-1143. (Pubitemid 24204197)
29. Marceau F, Sabourin T, Houle S, Fortin JP, Petitclerc E, Molinaro G et al. (2002). Kinin receptors: functional aspects. Int Immunopharmacol 2: 1729-1739.
30. Morissette G, Houle S, Gera L, Stewart JM, Marceau F (2007). Antagonist, partial agonist and antiproliferative actions of B-9870 (CU201) as a function of the expression and density of the bradykinin B1 and B2 receptors. Br J Pharmacol 150: 369-379. (Pubitemid 46221045)
31. Morissette G, Lodge R, Marceau F (2008). Intense pseudotransport of a cationic drug mediated by vacuolar ATPase: procainamideinduced autophagic cell vacuolization. Toxicol Appl Pharmacol 228: 364-377.
32. Munoz CM, Leeb-Lundberg LMF (1992). Receptor-mediated internalization of bradykinin. DDT1 MF-2 smooth muscle cells process internalized bradykinin via multiple degradation pathways. J Biol Chem 267: 303-309.
33. 2-receptor agonist, OPC-51803, administered orally to dogs. J Pharmacol Sci. 94: 426-433.
34. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS (2000). Differential affinities of visual arrestin, βarrestinl and βarrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 275: 17201-17210.
35. Perlman S, Schambye HT, Rivero RA, Greenlee WJ, Hjorth SA, Schwartz TW (1995). Non-peptide angiotensin agonist. Functional and molecular interaction with the ATI receptor. J Biol Chem 270: 1493-1496.
36. 2 receptor requires phosphorylation of three serine and two threonine residues at its carboxyl tail. J Biol Chem 274: 12738-12747.
37. 2 receptor antagonist. Immunopharmacology 43: 187-194.
38. Rizzi A, Rizzi C, Amadesi S, Calo G, Varani K, Inamura N et al. (1999). Pharmacological characterization of the first non-peptide bradykinin B2 receptor agonist FR 190997: an in vitro study on human, rabbit and pig vascular B2 receptors. Naunyn-Schmied Arch Pharmacol 360: 361-367. (Pubitemid 29502983)
39. Sawada Y, Kayakiri H, Abe Y, Mizutani T, Inamura N, Asano M et al. (2004a). A new class of nonpeptide bradykinin B2 receptor ligand, incorporating a 4-aminoquinoline framework. Identification of a key pharmacophore to determine species difference and agonist/ antagonist profile. J Med Chem 47: 2667-2677. (Pubitemid 38580103)
40. Sawada Y, Kayakiri H, Abe Y, Mizutani T, Inamura N, Asano M et al. (2004b). Discovery of the first non-peptide full agonists for the human bradykinin B2 receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks. J Med Chem 47: 2853-2863. (Pubitemid 38656738)
41. Simaan M, Bédard-Goulet S, Fessart D, Gratton JP, Laporte SA (2005). Dissociation of β-arrestin from internalized bradykinin B2 receptor is necessary for receptor recycling and resensitization. Cell Signal 17: 1074-1083. (Pubitemid 40933528)
42. Taraseviciene-Stewart L, Scerbavicius R, Stewart JM, Gera L, Demura Y, Cool C et al. (2005). Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides 26: 1292-1300. (Pubitemid 41021462)
43. Ueno A, Naraba H, Kojima F, Morita E, Oh-ishi S (1999). FR190997, a novel bradykinin B2 agonist, expresses longer action than bradykinin in paw edema formation and hypotensive response. Immunopharmacology 45: 89-93.
44. Vidal MA, Astroza A, Matus CE, Ehrenfeld P, Paviclc F, Sanchez T et al (2005). Kinin B2 receptor-coupled signa; transduction in human cultured keratinocytes. J Invest Dermatol 124: 178-186. (Pubitemid 40100967)
45. Violin JD, Lefkowitz RJ (2007). β-arrestin-biased ligands at seven- transmembrane receptors. Trends Pharmacol Sci 28: 416-422. (Pubitemid 47087969)
46. Wang JW, Su W, Law YP, Lu CH, Chen YC, Wang JL et al. (2001). Mechanisms of bradykinin-induced Ca2+ mobilization in MG63 human osteosarcome cells. Harm Res 55: 265-270. (Pubitemid 34114172)